Background
esophageal carcinoma, authorshipEsophageal cancer, aggressive neoplasm of the gastrointestinal tract
ONCOLOGY, DISEASE, RECURRENCE, ESOPHAGEAL CARCINOMA
Edited by: Simona Kranjc Brezar, Institute of Oncology Ljubljana, SloveniaReviewed by: Dapeng Lei, Shandong University, China; Haiping Jiang, Zhejiang University, China†These authors have contributed equally to this work and share first authorshipEsophageal cancer (EC) is an aggressive neoplasm of the gastrointestinal tract that is usually treated with a combination of chemotherapy, radiotherapy (RT), and/or surgery, according to disease status. Despite the availability of multimodal therapeutic strategies, local recurrence is frequently observed. However, there is no standard treatment or promising therapeutic approach for local recurrence or metastatic esophageal carcinoma after the RT. This study tended to investigate the efficacy and safety of sintilimab maintenance after concurrent chemoradiotherapy (CCRT) for local/regional recurrent esophageal squamous carcinoma.